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Purpose: To generate conclusive evidence regarding the noninferiority of intravitreal bevacizumab compared
with ranibizumab in patients with diabetic macular edema (DME).
Design: Comparative, randomized, double-masked, multicenter, noninferiority clinical trial.
Participants: Eligible patients were older than 18 years, diagnosed with type 1 or type 2 diabetes mellitus,
with glycosylated hemoglobin of less than 12%, central area thickness of more than 325 mm, and visual
impairment from DME with a best-corrected visual acuity (BCVA) between 24 letters and 78 letters.
Methods: From June 2012 through February 2018, a total of 170 participants were randomized to receive 6
monthly injections of either 1.25 mg bevacizumab (n ¼ 86) or 0.5 mg ranibizumab (n ¼ 84).
Main Outcome Measures: Primary outcome was change in BCVA from baseline to month 6 compared
between the 2 treatment arms. The noninferiority margin was 3.5 letters.
Results: The difference in mean BCVA between treatment arms was 1.8 letters in favor of ranibizumab after 6
months of follow-up; BCVA improved by 4.96.7 letters in the bevacizumab group and 6.78.7 letters in the
ranibizumab group. The lower bound of the 2-sided 90% confidence interval (CI) was e3.626 letters, exceeding
the noninferiority margin of 3.5 letters. Central area thickness decreased more with ranibizumab (138.2114.3
mm) compared with bevacizumab (64.2104.2 mm). In a post hoc subgroup analysis, participants with a worse
BCVA at baseline (69 letters) improved by 6.77.0 letters with bevacizumab and 10.410.0 letters with rani-
bizumab, and central area thickness decreased significantly more in the ranibizumab arm of this subgroup
compared with the bevacizumab arm. Participants with an initially better BCVA at baseline (70 letters) did not
demonstrate differences in BCVA or OCT outcomes between treatment arms.
Conclusions: Based on change in BCVA from baseline to month 6, the noninferiority of 1.25 mg
bevacizumab to 0.5 mg ranibizumab was not confirmed. Only the subgroup of patients with a lower BCVA at
baseline showed better visual acuity and anatomic outcomes with ranibizumab. Our study confirmed the potential
differential efficacy of antievascular endothelial growth factor agents in the treatment of DME as well as the
difference in response between patient groups with different baseline visual acuities. Ophthalmology
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bevacizumab is a low-priced alternative to the registered and
more expensive ranibizumab and aflibercept. However, only
1 state-of-the-art randomized clinical trial, the Diabetic
Retinopathy Clinical Research Network (DRCR.net) 2020 by the American Academy of Ophthalmology. This is an open access article
under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/
4.0/). Published by Elsevier Inc.Protocol T study, has compared the efficacy and safety of
these antievascular endothelial growth factor (VEGF)
agents directly in DME.1,2
Diabetic macular edema is the most important cause of
vision loss in patients with diabetic retinopathy (DR). It is777https://doi.org/10.1016/j.oret.2020.02.008
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leading to leakage of proteins and fluid from blood vessels,
tissue edema, and eventually neurodegeneration and per-
manent visual loss.3 Diabetic macular edema is associated
with a high patient burden and high societal costs because
of the growing number of patients with diabetes mellitus
and has become a serious global health issue.4e6
The pathophysiology of DME is multifactorial, complex,
and not fully understood. Vascular endothelial growth factor
A is a major mediator,7,8 according to the results of several
trials that demonstrated a positive effect on visual acuity
outcomes with anti-VEGF therapies compared with laser
photocoagulation or sham injections.9e12 The anti-VEGF
agents commonly used for the treatment of DME are rani-
bizumab, a humanized monoclonal antibody fragment;
bevacizumab, a humanized full-length monoclonal antibody
that, like ranibizumab, neutralizes all VEGF A isoforms7;
and aflibercept, a construct of 2 VEGF receptors fused to
a humanized monoclonal antibody backbone.13
Only ranibizumab and aflibercept are registered as treat-
ment for macular edema, but bevacizumab is used off-label
because its cost is 20- to 40-fold lower compared with the
other drugs. In the DRCR.net Protocol T study comparing the
3 agents, after 1 year, aflibercept was more effective in
improving visual acuity compared with bevacizumab or
0.3-mg ranibizumab. However, these findings were not
interpreted as clinically meaningful because they were driven
by baseline visual acuity. In fact, aflibercept was superior to
bevacizumab and 0.3-mg ranibizumab only in a subgroup of
patients with a baseline visual acuity of less than 69 letters.
After 2 years, aflibercept was superior only to bevacizumab
in this subgroup of patients.1,2 One other small randomized
clinical trial of 63 eyes demonstrated no difference between
bevacizumab and ranibizumab in effects on central area
thickness and visual acuity after 1 year of monthly
injections, but that study was not powered to detect small
but clinically meaningful differences.14 In the present
study, we aimed to generate conclusive evidence regarding
the noninferiority of 1.25 mg bevacizumab to ranibizumab
at a higher dose of 0.5 mg in patients with DME in terms of
visual acuity outcomes.Methods
Study Design and Population
The study protocol has been detailed previously.15 In summary, the
Bevacizumab and Ranibizumab in Diabetic Macular Edema
(BRDME) trial was a prospective, randomized, double-masked
clinical trial with a noninferiority design performed in 8 clinical
centers throughout The Netherlands. The Medical Ethical Com-
mittee of the Amsterdan University Medical Centers, location
AMC, approved the trial protocol, and the study adhered to the
principles of the Declaration of Helsinki. All participants signed
written informed consent before screening. The trial is registered at
ClinicalTrials.gov (identifier, NCT01635790) and at the Dutch trial
register (identifier, NTR3247).
From June 2012 through February 2018, a total of 170 partic-
ipants were screened for eligibility. Eligible patients were older
than 18 years, diagnosed with type 1 or type 2 diabetes mellitus
and with a glycosylated hemoglobin of less than 12%, central area778thickness on optical coherence tomography (OCT) of more than
325 mm, and visual impairment resulting from DME with best-
corrected visual acuity (BCVA) outcome of at least 24 letters
and less than 79 letters on standardized Early Treatment Diabetic
Retinopathy Study charts. A complete list of inclusion and exclu-
sion criteria are found in Table S1 (available at
www.ophthalmologyretina.org). At the screening visit, we
verified that glycosylated hemoglobin levels were less than 12%.
However, the actual values of glycosylated hemoglobin were not
recorded. The diagnosis of DME and DR, together with
fulfillment of eligibility criteria, was validated through spectral-
domain OCT and fluorescein angiography examination and was
reviewed by an independent reading center (the Belfast Reading
Center, Belfast, United Kingdom, part of the Network of
Ophthalmic Reading Centers of the United Kingdom).
Interventions and Randomization
After giving written informed consent and completing a successful
screening visit, participants were assigned randomly to receive
intravitreal injections of either 1.25 mg bevacizumab (Avastin;
Genentech, South San Francisco, CA, United States/Hoffman-La
Roche, Basel, Switzerland) or 0.5 mg ranibizumab (Lucentis;
Genentech, South San Francisco, CA, United States/Novartis, Inc,
Basel, Switzerland). Randomization was stratified by center, the
BCVA of the study eye (52 letters vs. 53 letters),16,17 and
central area thickness on spectral-domain OCT (400 mm or
>400 mm). Permuted blocks (block size minimum, 2 patients;
block size maximum, 4 patients) were used, and allocation was
computer- and internet-based. Each participant received a unique
patient identification number at randomization.
Within 14 days after screening, study participants received their
first injection at the baseline visit. The hospital pharmacy recon-
stituted and supplied the study drug in injection syringes, labeled
with only a patient identification number. Thus, all study partici-
pants, investigator staff, and treating physicians were unaware of
treatment allocation. Over the course of 6 months, patients received
6 monthly injections with an interval of 307 days between visits.
Best-corrected visual acuity of the study eye was determined at
every visit together with spectral-domain OCT examination and
basic clinical examination (pulse and blood pressure measure-
ment). At screening and exit visits, a more extensive dilated
ophthalmic examination was performed together with fluorescein
angiography and color fundus photography of both eyes. During
each visit, concomitant medication, adverse events (AEs), and
severe AEs (SAEs) were registered. Best-corrected visual acuity
was measured by trained personnel following protocol and using
the standardized Early Treatment Diabetic Retinopathy Study
chart. Retinal area thickness was examined with the system
available at the participating center (Zeiss Cirrus, Heidelberg
Spectralis, or Topcon). OCT values obtained by Zeiss Cirrus (Carl
Zeiss Meditec, Dublin, Ireland) or Topcon (Topcon, Tokyo, Japan)
devices were converted to Heidelberg Spectralis (Heidelberg En-
gineering, Heidelberg, Germany) values for analysis and reporting,
using the conversion table reported by Giani et al.18
Outcomes
The primary outcome was the difference in BCVA change in the
study eye from baseline to month 6 between treatment arms, with a
noninferiority margin of 3.5 letters. Prespecified secondary out-
comes were the proportion of participants with a BCVA loss or
gain of fewer than 15 letters from months 0 to 6 (stabilizers), with a
BCVA loss of 15 letters or more (nonresponders), or with a BCVA
gain of 15 letters or more (gainers). Secondary outcomes included
change in central area thickness as measured by spectral-domain
Vader et al  Bevacizumab and Ranibizumab for DMEOCT at 6 months, change in intraocular pressure from baseline to
month 6, the proportion of dropouts before the final examination at
6 months, and the occurrence of SAEs and AEs during the study
period. All AEs were coded according the Medical Dictionary for
Regulatory Activities system version 20.0.
Participants were randomized based on their visual acuity at
baseline (52 letters vs. 53 letters). However, the number of
patients between groups was misaligned so that the group with a
baseline BCVA of 53 letters or more had 156 participants
compared with 10 participants in the group with a baseline BCVA
of 52 letters or fewer. To yield equally distributed groups for sta-
tistical analysis, we followed the methods of the Protocol T study
of the DRCR.net, using the median letter score at baseline as a
cutoff value for subgroup analysis.1,2 The baseline median in our
study was 70 letters in each group; therefore, we performed a
post hoc analysis comparing visual acuity and retinal thickness
outcomes of patients with a higher baseline visual acuity (70
letters; Snellen equivalent, approximately >20/40) with patients
with a lower baseline visual acuity (69 letters; Snellen
equivalent, approximately 20/40).
The Belfast Reading Center confirmed the diagnosis of DR and
DME and checked adherence to inclusion and exclusion criteria.
Furthermore, they classified DR into nonproliferative DR (NPDR),
stable proliferative DR (PDR), and active PDR. The classification
into NPDR included all severities of NPDR of the Early Treatment
Diabetic Retinopathy Study diabetic retinopathy severity scale.
Stable PDR was identified by the absence of leakage resulting from
a neovascularization on the fluorescein angiogram, in the presence
of laser scars, fibrous proliferations, or both. Active PDR was
classified as definite leakage on fluorescein angiogram resulting
from a neovascularization on the disc or elsewhere, the presence of
a preretinal hemorrhage or a vitreous hemorrhage, including retinal
laser scars, or both. For this reason, we performed another post hoc
analysis comparing primary and secondary outcomes between
treatment groups in patients classified with NPDR and with stable
and active PDR. Other secondary outcomes that have been
described in the study protocol15 will be presented in separate
reports.
Sample Size Calculation
At the start of the study, the sample size for an 80% power of
demonstrating noninferiority was based on the standard deviation
(SD) of the change in a visual acuity score of 11 letters from baseline
to month 6.9 According to this calculation, 123 patients in each
study arm would be needed to demonstrate noninferiority, given a
noninferiority margin of 3.5 letters. A mean improvement of 7
letters reflected the average change in visual acuity observed in
placebo-controlled trials with ranibizumab.10,19e21 The non-
inferiority margin was set equivalent to less than half of this
improvement.
In February 2018, the assumed SD of the change in BCVA was
checked on the blinded study data, yielding a lower SD of 7.8
letters. Given this lower SD and still assuming an improvement of
7 letters, a sample size of 126 patients (63 in each study arm)
would have an 80% power of demonstrating noninferiority by
excluding a difference of 3.5 letters or more at a 1-sided a sig-
nificance level of 0.05.
Statistical Analysis
Statistical analysis was based on the intention-to-treat principle.
Participants who received the allocated treatment at least once,
along with OCT examination and BCVA measurements 1 month
after the last injection, were included. If participants did not
complete the study, the last available BCVA was used as theBCVA at month 6 (last observation carried forward). The latter
approach also was applied when patients missed an injection
during follow-up: the BCVA measurement from the previous visit
was used as the last available BCVA. Noninferiority was tested
using a 1-sided t test. Bevacizumab was considered noninferior to
ranibizumab if the lower bound of the 2-sided 90% confidence
interval (CI) of the difference in visual acuity did not exceed the
noninferior margin of 3.5 letters. The 2-sided 90% CI is equivalent
to the 1-sided 95% CI, which is used as the outcome measurement
in noninferiority trials.
To evaluate the influence of using the last observation carried
forward, we performed a linear mixed-effects regression analysis to
analyze the repeatedly measured BCVA change from baseline to
month 6. For the analysis of the proportion of nonresponders,
stabilizers, and gainers between treatment groups, we used the
linear-by-linear association test. The difference in the number of
dropouts was analyzed with the Pearson chi-square test. Covari-
ance analysis was completed to compare change in central area
thickness and change in intraocular pressure from baseline to
month 6 between treatment groups. The numbers and proportion of
SAEs and AEs per study arm were compared using the
ManneWhitney U test and the Pearson chi-square test. For all
statistical tests, a significance level of 0.05 was applied. These
statistical tests also were used for primary and secondary outcomes
in post hoc analyses.Results
Study Participants
From June 2012 through February 2018, a total of 170 participants
were randomized to receive bevacizumab (n ¼ 86) or ranibizumab
(n ¼ 84). The extensive inclusion and exclusion criteria of the
study protocol and a decrease in referrals to the academic study
sites caused the prolonged inclusion period. Eventually, 84 patients
receiving bevacizumab and 82 patients receiving ranibizumab were
included in primary and secondary analyses (Fig S1, available at
www.ophthalmologyretina.org).
In general, ocular and demographic baseline characteristics did
not differ between treatment groups (Table 1). Only a difference in
gender distribution was noted (P ¼ 0.024), with 40 women
included in the bevacizumab group compared with 25 women in
the ranibizumab group. Nonwhite participants were distributed
evenly among the treatment groups (P ¼ 0.530).
The presence of DME secondary to DR was confirmed for all
patients by the Belfast Reading Center. Fulfillment of all eligibility
criteria could not be confirmed in all participants because 22 pa-
tients showed the exclusion criteria of untreated PDR in the study
eye (n ¼ 4) or structural damage within 600 mm of the center of the
macula (n ¼ 18). Untreated PDR was defined as leakage on
fluorescein angiogram resulting from a neovascularization, the
presence of preretinal hemorrhages or vitreous hemorrhages, or
both, without the detection of retinal laser scars. Structural damage
included the presence of laser scars, retinal pigment epithelium
atrophy, and organized hard exudate plaques close to the macula.
These 22 participants were distributed evenly over both treatment
arms (13 [15.5%] in the bevacizumab group and 9 [11.0%] in the
ranibizumab group; P ¼ 0.393). The mean  SD baseline visual
acuity of the study eye of these 22 patients was 65.510.9 letters in
the bevacizumab arm and 73.86.7 letters in the ranibizumab arm
(P ¼ 0.057). However, because our statistical analysis is based on779
Table 1. Baseline and Demographic Characteristics
Baseline Characteristics Bevacizumab (n [ 84) Ranibizumab (n [ 82)
Mean age (SD), yrs 63.9 (11.6) 64.9 (11.6)
Gender, no. (%)*
Female 40 (47.6) 25 (30.5)
Male 44 (52.4) 57 (69.5)
Ethnicity, no. (%)
Dutch 60 (71.4) 67 (81.7)
Moroccan 3 (3.6) 1 (1.2)
Turkish 1 (1.2) 0
Surinamese 10 (11.9) 9 (11.0)
Netherlands Antilles and Aruba 1 (1.2) 0
Other nonwhite participants 8 (9.5) 5 (6.1)
Other white participants 1 (1.2) 0
Smoking behavior, no. (%)
Smoker 9 (10.7) 10 (12.2)
Former smoker 39 (46.4) 39 (47.6)
Nonsmoker 36 (42.9) 33 (40.2)
Mean visual acuity of the study eye (SD), letters 69.0 (1.0) 68.5 (10.2)
Mean central area thickness (SD), mm 450.2 (91.9) 465.9 (104.6)
Mean intraocular pressure (SD), mmHg 15.0 (3.1) 15.0 (3.7)
Prior anti-VEGF treatment in study eye, no. (%) 14 (16.7) 17 (20.7)
Prior focalegrid photocoagulation treatment in the study eye, no. (%) 11 (12.8) 13 (15.5)
Prior panretinal photocoagulation treatment in the study eye, no. (%) 13 (15.1) 14 (16.7)
Diabetes mellitus type, no. (%)
Type I 10 (11.9) 12 (14.5)
Type II 74 (88.1) 71 (85.5)
Mean duration of diagnosis of diabetes mellitus (SD), yrs 15.4 (8.8) 17.5 (13.4)
Diabetic retinopathy severity, no. (%)
NPDR 37 (44.0) 41 (50.0)
Active PDR 19 (22.7) 10 (12.2)
Stable PDR 28 (33.3) 30 (36.6)
Missing 0 1 (1.2)
Mean blood pressure (SD), mmHg
Systolic 144.5 (15.4) 143.9 (17.3)
Diastolic 78.8 (10.4) 80.2 (10.7)
Mean body mass index (SD), m2/kg 28.9 (0.6) 29.1 (4.9)
Insulin use, no. (%) 54 (64.3) 55 (67.1)
Presence of intraretinal cysts in the study eye, no. (%)
Absent 2 (2.4) 0
Definite 81 (96.4) 82 (100)
Questionable 1 (1.2) 0
Presence of subretinal fluid in the study eye, no. (%)
Absent 51 (60.7) 48 (58.5)
Definite 20 (23.8) 25 (30.5)
Questionable 12 (14.3) 9 (11.0)
Could not be graded 1 (1.2) 0
History of hypertension, no. (%) 55 (65.5) 57 (69.5)
History of myocardial infarction, no. (%) 6 (7.1) 8 (9.8)
History of transient ischemic attack, no. (%) 6 (7.1) 4 (4.9)
History of cerebrovascular accident, no. (%) 5 (6.0) 4 (4.9)
History of hypercholesterolemia, no. (%) 17 (20.2) 19 (23.2)
History of thrombosis, no. (%) 2 (2.4) 1 (1.2)
History of renal disease, no. (%) 8 (9.5) 10 (12.2)
NPDR ¼ nonproliferative diabetic retinopathy; PDR ¼ proliferative diabetic retinopathy; SD ¼ standard deviation; VEGF ¼ vascular endothelial growth
factor.
*A significant difference was found between treatment groups with P < 0.05.
Ophthalmology Retina Volume 4, Number 8, August 2020the intention-to-treat principle, all randomized participants were
included in the analyses.
In addition, among the 166 participants analyzed, 6 participants
(7.1%) in the bevacizumab group and 2 participants (2.4%) in the780ranibizumab group dropped out of the study before the final
6-month assessment (P ¼ 0.157). No difference was found in the
mean number of injections between treatment groups for partici-
pants who completed the entire study protocol. Patients in the







Confidence Interval* P Value
Primary
Mean change in visual acuity of study eye from months 0 to 6 (SD), letters
Month 1 1.5 (5.7) 3.3 (6.0) e3.241
Month 2 3.8 (5.2) 5.1 (6.6) e2.762
Month 3 4.2 (5.8) 5.7 (8.5) e3.158
Month 4 4.6 (6.7) 5.8 (8.8) e2.933
Month 5 4.9 (7.0) 6.6 (8.8) e3.543
Month 6 4.9 (6.7) 6.7 (8.7) e3.626
Mean visual acuity of the study eye at 6 months (SD), letters 73.5 (9.8) 75.2 (9.0)
Secondary
Change in visual acuity, no. (%) 0.105
Stabilizers (loss or gain <15 letters from baseline) 81 (94.2) 73 (86.9)
Nonresponders (loss 15 letters from baseline) 0 0
Gainers (gain 15 letters from baseline) 5 (5.8) 11 (13.1)
Mean central area thickness at 6 months (SD), mm 383.40 (102.64) 327.40 (67.23) 0.000
Mean change in central area thickness (SD), mm 0.000
Month 1 e49.8 (76.6) e86.0 (111.5)
Month 2 e56.9 (90.4) e108.4 (115.7)
Month 3 e66.2 (96.7) e107.6 (116.6)
Month 4 e64.7 (91.3) e119.7 (116.2)
Month 5 e67.5 (97.4) e132.0 (114.7)
Month 6 e64.2 (104.2) e138.2 (114.3)
Intraretinal cysts on OCT at 6 mos, no. (%) 0.107
Absent 8 (10.7) 12 (15.8)
Definite 64 (85.3) 55 (72.4)
Questionable 3 (4.0) 9 (11.8)
Subretinal fluid on OCT at 6 mos, no. (%) 0.028
Absent 60 (80.0) 68 (89.5)
Definite 11 (14.7) 2 (2.6)
Questionable 4 (5.3) 6 (7.9)
Proportion of dropouts, no. (%) 6 (7.1) 2 (2.4) 0.157
Mean change in systolic blood pressure from month 0 to 6 (SD), mmHg 2.4 (16.3) 4.9 (17.2) 0.262
Mean systolic blood pressure at 6 months (SD), mmHg 146.2 (19.5) 149.5 (16.6)
Mean change in diastolic blood pressure from month 0 to 6 (SD), mmHg 0.03 (8.2) e1.0 (10.2) 0.854
Mean diastolic blood pressure at 6 months (SD), mmHg 78.0 (11.0) 79.4 (11.4)
Mean change in IOP from month 0 to 6 (SD), mmHg 0.2 (3.7) e0.1 (2.9) 0.718
Mean IOP at 6 months (SD), mmHg 15.0 (3.5) 15.0 (3.4)
IOP ¼ intraocular pressure; SD ¼ standard deviation.
*The lower bound of the 2-sided 90% confidence interval of the difference in visual acuity change is noted as an outcome for noninferiority; bevacizumab is
considered noninferior to ranibizumab if the noninferiority margin of 3.5 letters can be excluded.
Vader et al  Bevacizumab and Ranibizumab for DMEbevacizumab group received 5.950.03 injections and patients in
the ranibizumab group received 5.980.02 injections (P ¼ 0.391).
The mean follow-up time between visits was 29.71.4 days in the
bevacizumab group and 29.51.1 days in the ranibizumab group
(P ¼ 0.450).
Visual Acuity Outcomes
The mean visual acuity improved from baseline to 6 months by
4.96.7 letters in the bevacizumab group and 6.78.7 letters
in the ranibizumab group (Table 2; Fig 1A). The lower bound
of the 2-sided 90% CI for change in visual acuity from
baseline to month 6 was e3.626 letters, exceeding the non-
inferiority margin of 3.5 letters (Fig 2). (These outcomes were
verified with linear mixed-effects regression analysis, in which
case the lower bound of the 2-sided 90% CI was e3.844
letters.The proportion of stabilizers, nonresponders, and gainers did
not differ between treatment arms (P ¼ 0.105), with 5 gainers
(5.8%) in the bevacizumab group and 11 gainers (13.1%) in the
ranibizumab group. The number of stabilizers was distributed
equally over the 2 treatment arms, and no patients lost 15 letters or
more from baseline.
Post hoc analysis was performed based on the median letter
score at baseline, comparing participants with a baseline visual
acuity of 69 letters or fewer (n ¼ 79) with participants with a
baseline visual acuity of 70 letters or more (n ¼ 87; Table 3). In
both subgroups, participants were distributed equally over the
treatment arms (Table 3). Patients with an initially lower BCVA
showed a mean gain of 6.77.0 letters when receiving
bevacizumab and 10.410.0 letters when receiving ranibizumab,
with the lower bound of the 2-sided 90% CI at e6.430 letters
(Table 3; Figs 1B and 3). Again, this result excludes the
noninferiority margin of 3.5 letters, but this subgroup was not781
Figure 1. Graphs showing mean change in visual acuity from baseline to month 6 in patients treated with bevacizumab and ranibizumab: (A) entire cohort,
(B) patients with a baseline visual acuity of 69 letters or fewer, and (C) patients with a baseline visual acuity of 70 letters or more. BCVA ¼ best corrected
visual acuity; CI ¼ confidence interval.
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higher BCVA improved by 3.15.9 letters in the bevacizumab
group and 3.65.7 letters in the ranibizumab group, with a
lower bound of the 2-sided 90% CI at e2.566 letters, suggesting
noninferiority of bevacizumab to ranibizumab in this subgroup
(Table 3; Figs 1C and 3).
Additional analyses excluding the 22 patients who did not
meet all eligibility criteria again demonstrated noninferiority in the
subgroup with a higher baseline BCVA only (results not shown).
The 22 patients were distributed equally over the subgroups with a
lower and higher baseline visual acuity. When we analyzed these
22 participants exclusively, the mean visual acuity improved with
8.35.7 letters in the bevacizumab arm and with 1.63.7 letters in
the ranibizumab arm from baseline to 6 months.
Central Area Thickness Outcomes
After 6 months, central area thickness decreased in the bev-
acizumab arm by a mean of 64.2104.2 mm and in the ranibizu-
mab arm by a mean of 138.2114.3 mm (P < 0.001; Table 2; Fig
3A). The presence of intraretinal cysts and subretinal fluid did not
differ between treatment arms at baseline visit (Table 2). However,
after 6 months, more patients demonstrated subretinal fluid in the
bevacizumab group (11 patients [14.7%]) than in the
ranibizumab group (2 patients [2.6%]; P ¼ 0.028). In the
subgroup of participants with a baseline visual acuity of 69 letters782or fewer, central area thickness decreased by 58.7114.2 mm
in the bevacizumab group and by 189.5137.3 mm in the
ranibizumab group (P < 0.001; Table 3; Fig 3B). Those with an
initially better visual acuity (70 letters) showed a decrease in
central area thickness of 69.295.3 mm in the bevacizumab group
and 95.166.0 mm in the ranibizumab group (P ¼ 0.073; Table 3;
Fig 3C). When we excluded the 22 patients who did not meet all
eligibility criteria, again ranibizumab decreased central area
thickness significantly more compared with bevacizumab, both in
the entire cohort and in the subgroup with a lower baseline BCVA.Subgroup Analysis: Diabetic Retinopathy
Severity Score
Of all patients randomized, 78 patients were diagnosed with
NPDR, 29 patients were diagnosed with active PDR, and 58 pa-
tients were diagnosed with stable PDR (Table S2, available at
www.ophthalmologyretina.org). The Belfast Reading Center
could not diagnose 1 patient because of missing proper imaging
material. For analysis, patients with active and stable PDR were
merged into 1 PDR subgroup. In the NPDR group, the mean
gain in visual acuity after 6 months was 5.56.3 letters in those
randomized to receive bevacizumab and 8.710.7 letters in those
randomized to receive ranibizumab (lower bound of the 2-sided
90% CI for the difference in change in visual acuity was e5.721
Figure 2. Graph showing the 2-sided 90% confidence intervals (CIs) with
the noninferiority margin of 3.5 letters. Noninferiority of bevacizumab
compared with ranibizumab could not be confirmed in the entire study
cohort, although the lower bound of the CI just exceeded the non-
inferiority margin of 3.5 letters. In patients with a lower baseline visual
acuity, noninferiority of bevacizumab could not be confirmed either,
whereas the CIs for patients with a higher baseline visual acuity suggested
noninferiority of bevacizumab to ranibizumab. However, these subgroups
were not powered to demonstrate noninferiority reliably. BCVA ¼ best
corrected visual acuity.
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however, again, this subgroup was not powered to reject non-
inferiority. In patients diagnosed with PDR, the mean gain in visual
acuity was almost equal in both treatment groups, with a gain of
4.47.0 letters in the bevacizumab group and 4.75.6 letters in the
ranibizumab group (lower bound of the 2-sided 90% CI, e2.558
letters; Table S2), suggesting noninferiority of bevacizumab to
ranibizumab in this subgroup.
A significant difference between bevacizumab and ranibizumab
in the change of central area thickness after 6 months of treatment
was detected solely in the subgroup with patients diagnosed with
PDR (P ¼ 0.001). However, when we excluded the 22 patients
who did not meet all eligibility criteria, patients in the PDR sub-
group who were treated with ranibizumab demonstrated a larger
gain in visual acuity compared with those who were treated with
bevacizumab, and noninferiority of bevacizumab to ranibizumab
no longer could be confirmed. This additional analysis did not alter
visual acuity outcomes in the NPDR subgroup. Besides, secondary
outcomes regarding the change in central area thickness did not
differ when these 22 patients were excluded from analyses in both
subgroups.Safety Outcomes
The number of patients who experienced AEs and SAEs during the
study period did not differ between the bevacizumab and ranibi-
zumab groups (P ¼ 0.704 and P ¼ 0.711, respectively). Arterio-
thrombotic events were distributed equally over both study arms: 1
patient in the bevacizumab group experienced a nonfatal stroke,
and 1 patient in the ranibizumab group experienced a myocardial
infarction (Table 4). A difference between treatment groups was
identified in the Medical Dictionary for Regulatory Activities
system organ class of immune system disorders (P ¼ 0.014);AEs described in this class consisted solely of allergic reactions
resulting from fluorescein angiography. Another difference was
found in the system organ class of injury, poisoning and
procedural complication (P ¼ 0.005; Table S3, available at
www.ophthalmologyretina.org), which included the occurrence of
physical injuries and the presence of floaters after injection.
Nevertheless, the AEs described in these system organ classes
are not likely to be of clinical significance and were not
considered to be caused by the anti-VEGF agent itself. Intraoc-
ular pressure changed minimally over the course of 6 months in
both the bevacizumab and ranibizumab groups (Table 2).Discussion
This study showed that based on the change in visual acuity
from baseline to month 6, noninferiority of 1.25-mg bev-
acizumab to 0.5-mg ranibizumab could not be confirmed in
patients with DME, because the lower bound of the 2-sided
90% CI of e3.626 letters exceeded the noninferiority
margin of 3.5 letters. When patients were analyzed based on
baseline visual acuity, bevacizumab was noninferior to
ranibizumab in patients with an initially higher visual acuity
(70 letters). Because ranibizumab showed a much better
outcome in patients with an initially lower BCVA (69
letters), it is plausible that participants with a lower baseline
visual acuity drove the visual acuity outcome of the entire
study group. The subgroup with a lower baseline BCVA
was not powered to reject noninferiority of bevacizumab to
ranibizumab, but we considered the substantial difference of
3.7 letters in favor of ranibizumab to be clinically relevant.
In addition, ranibizumab showed better visual acuity out-
comes in participants diagnosed with NPDR, in contrast to
results in PDR patients, in whom visual acuity improved
equally in both treatment arms.
The Protocol T study of the DRCR.net is the largest
study to date to compare the efficacy and safety of all 3 anti-
VEGF agents in patients with DME, with ranibizumab used
in the 0.3-mg dose. After 1 year of follow-up, aflibercept
was linked to a larger improvement in visual acuity than
bevacizumab and 0.3-mg ranibizumab. The DRCR.net
stated that these outcomes were not clinically meaningful to
all patients, because a subgroup analysis showed significant
outcomes in favor of aflibercept over both bevacizumab and
ranibizumab in only those patients with an initially lower
visual acuity. The 2-year results demonstrated that afli-
bercept continued to be significantly more effective
compared with bevacizumab in this subgroup.1,2 As noted,
our study showed that 0.5-mg ranibizumab had better out-
comes compared with bevacizumab in terms of both visual
acuity and anatomic outcomes. Nevertheless, when patients
were divided into subgroups with a higher or lower baseline
visual acuity, these results persisted only in the group with
an initially lower BCVA and were absent in patients with an
initially higher BCVA, similar to the observations in the
protocol T study.
In contrast to our findings, in the Protocol T study, bev-
acizumab and ranibizumab did not differ significantly in visual
acuity outcomes after either 1 or 2 years of treatment. This
difference between the 2 studies may be explained by the783
Table 3. Primary and Secondary Outcomes Based on Baseline Visual Acuity
Outcomes













Confidence Intervaly P Value
Primary
Visual acuity at baseline, letters 74.7 (3.2) 75.0 (3.6) 62.1 (8.5) 60.8 (10.2)
Change in visual acuity of study eye,
letters
Month 1 0.8 (4.3) 2.0 (4.9) e2.944 2.3 (6.8) 4.8 (6.9) e5.012
Month 2 2.3 (4.5) 3.5 (4.2) e2.780 5.4 (5.4) 7.1 (8.3) e4.190
Month 3 2.2 (4.8) 2.6 (5.5) e2.316 6.2 (6.1) 9.3 (10.0) e5.622
Month 4 2.3 (5.8) 2.1 (5.3) e1.763 6.9 (6.9) 10.1 (10.1) e5.855
Month 5 2.7 (6.0) 3.6 (5.6) e3.005 7.3 (7.4) 10.2 (10.4) e5.886
Month 6 3.1 (5.9) 3.6 (5.7) e2.566 6.7 (7.0) 10.4 (10.0) e6.430
Visual acuity at 6 months, letters 77.9 (6.5) 78.59 (5.97) 68.80 (10.53) 71.25 (10.35)
Secondary
Central area thickness at baseline, mm 435.16 (83.65) 431.64 (67.61) 456.96 (98.32) 505.46 (125.03)
Change in central area thickness, mm
Month 1 e50.8 (61.5) e50.9 (63.6) e48.8 (90.6) e124.8 (138.3)
Month 2 e60.4 (82.4) e68.7 (62.8) e53.1 (99.9) e155.7 (144.2)
Month 3 e58.2 (77.1) e73.1 (65.2) e75.0 (115.1) e148.7 (148.2)
Month 4 e61.4 (84.5) e82.1 (63.3) e68.7 (99.9) e162.2 (145.4)
Month 5 e63.9 (93.5) e90.3 (60.7) e71.7 (102.9) e180.5 (141.7)
Month 6 e69.2 (95.3) e95.1 (66.0) 0.073 e58.7 (114.2) e189.5 (137.3) 0.000 0.004
Central area thickness at 6 months, mm 362.5 (71.8) 336.6 (69.6) 406.5 (125.5) 316.5 (63.5)
Data are mean (standard deviation).
*P value for best-corrected visual acuity at baseline  treatment group interaction on both visual acuity outcome and central area thickness outcome.
yThe lower bound of the 2-sided 90% confidence interval of the difference in best-corrected visual acuity change is noted as an outcome for noninferiority; bevacizumab is considered noninferior to


















Table 4. Numbers and Percentages of Patients with Adverse









Any adverse event 55 (64.7) 58 (69.9) 0.704
Elevated intraocular pressure 1 (1.2) 1 (1.2) 0.986
Anterior uveitis 1 (1.2) 3 (3.6) 0.300
Retinal tear 0 1 (1.2) 0.310
Hypertension 9 (10.6) 15 (18.1) 0.166
>1 Adverse event 29 (34.1) 28 (33.7) 0.958
Severe adverse events
Any severe adverse event 11 (13) 9 (10.8) 0.711
Death from any cause 2 (2.4) 0 0.160
Arteriothrombotic event
Nonfatal myocardial infarction 0 1 (1.2) 0.310
Nonfatal stroke 1 (1.2) 0 0.322
Wound resulting from vascular
problems
1 (1.2) 2 (2.4) 0.546
Transient ischemic attack 2 (2.4) 0 0.160
>1 Severe adverse event 2 (2.4) 3 (3.6) 0.630
Pneumonia 1 (1.2) 1 (1.2) 0.986
Urosepsis 2 (2.4) 1 (1.2) 0.574
Data are no. (%).
*Multiple events in the same study patient were counted only once.
Figure 3. Graphs showing mean change in central area thickness (in micrometers) from baseline to month 6: (A) entire cohort, (B) patients with a baseline
visual acuity of 69 letters or fewer, and (C) patients with a baseline visual acuity of 70 letters or more.
Vader et al  Bevacizumab and Ranibizumab for DMEchoice of study design, because the BRDME Study was con-
ducted as a noninferiority trial to describe visual acuity out-
comes, of which the lower bound of the 2-sided 90% CI was
given as a measure for outcome differences between anti-
VEGF agents, instead of P values as used in the Protocol T
study. In addition, because the Protocol T study investigated
0.3-mg ranibizumab instead of the 0.5-mg dose in the BRDME
Study, a dose-response effect may explain the different out-
comes of these studies. However, the RISE and RIDE studies
found no difference in visual acuity outcomes between patients
treated with 0.3-mg ranibizumab or 0.5-mg ranibizumab when
administered monthly for 3 years.9,22 A possible explanation
therefore may lie in the different treatment regimens of the 2
studies, which may have led to underdosing in the protocol T
study. In contrast to the monthly dosing in the BRDME
Study, the protocol T study showed more similarities with a
pro re nata protocol, in which patients are treated as needed,
which led to an average monthly dose of 0.235 mg of
ranibizumab in the first 12 months of the protocol T study.
However, because patients might be injected more frequently
in the first 6 months compared with the second 6 months of
the protocol T study, the average monthly dose of
ranibizumab in the first 6 months of the protocol T study
varies between 0.235 mg and 0.3 mg. Therefore, it is
difficult to compare the outcomes of the protocol T study
with those of the BRDME Study.785
Ophthalmology Retina Volume 4, Number 8, August 2020In line with the visual acuity outcomes, central area
thickness decreased significantly more in the ranibizumab
arm in the entire cohort, and more patients in the bev-
acizumab group showed subretinal fluid on OCT after 6
months of treatment (P ¼ 0.028). However, it should be
kept in mind that the presence or absence of subretinal fluid
was scored by local investigators and was not confirmed by
an external reading center. Nevertheless, similar findings
were seen in the Comparison of Age-Related Macular
Degeneration Treatments Trials (CATT) and the Bev-
acizumab to Ranibizumab in exudative Age-Related Mac-
ular Degeneration (BRAMD) study, both of which
compared the efficacy of bevacizumab with that of ranibi-
zumab in patients with exudative age-related macular
edema.23,24 In the subgroup analysis based on baseline
visual acuity, again, anatomic outcomes matched visual
acuity outcomes, where ranibizumab decreased the central
area thickness significantly more among patients with an
initially lower baseline visual acuity.
It is important to note that the observed different func-
tional and anatomic outcomes in the subgroups based on
baseline visual acuity may be explained in part or
completely by the ceiling effect originating from the phys-
iologic limits of both BCVA and OCT measurement out-
comes. The closer these parameters at baseline lie to the
ceiling of normal BCVA or retinal thickness, the less there
is to gain from a given treatment. In addition, it is unknown
whether the true gains of functional visual outcome or
quality of life differ per 1-letter increase or per 1-mm central
area thickness decline between these subgroups. That is, for
example, a gain of 3.7 letters may have a different functional
significance in the subgroup with a lower baseline visual
acuity than in the subgroup with a higher baseline visual
acuity.25,26
Noninferiority of bevacizumab to ranibizumab could be
confirmed in the PDR subgroup, which included patients
with active and stable PDR, but not in the subgroup of
patients with NPDR. Besides, patients in the latter subgroup
demonstrated a better gain in visual acuity compared with
patients with PDR, regardless of the treatment arm.
Although these subgroups were not powered to reject non-
inferiority, the reasons for these differences between DR
subgroups remain unclear. That these differences may be the
result of chance or confounding is supported by our finding
that the 22 patients who did not meet all eligibility criteria
were overrepresented in the PDR group, and when we
excluded these patients from analysis, noninferiority no
longer could be confirmed in the PDR subgroup, either.
A significant difference in gender distribution over the
treatment arms was found, because more women were
included in the bevacizumab arm compared with the rani-
bizumab arm. Because gender is not considered as one of
the risk factors for the development of DME or its response
to anti-VEGF therapy, this unbalance in patient groups is
unlikely to influence study outcomes.
The safety of intravitreal injections with anti-VEGF
agents remains incompletely understood. Treatment with
intravitreal anti-VEGF agents suppresses systemic VEGF,
which potentially can result in cardiovascular and arterio-
thrombotic events, wound healing complications, and786hypertension.27,28 In our study, we found no differences
between bevacizumab and ranibizumab groups in
cardiovascular and arteriothrombotic events or
hypertension, although our study was not powered to
detect small but clinically significant safety differences
between bevacizumab and ranibizumab. Differences were
found in Medical Dictionary for Regulatory Activities
classes of immune system disorders and injury, poisoning
and procedural complications. However, these AEs were
not caused directly by the anti-VEGF treatment itself.
According to the pharmacymanual of the study (Appendix
S1, available at www.ophthalmologyretina.org), the good
laboratory practiceecertified hospital pharmacies prepared
multiple doses of study medication from single vials, under
aseptic conditions. In the literature, this procedure has been
associated with contamination with silicone droplets.29
Nevertheless, no AEs that could be attributed to this
procedure were reported. In addition, no silicone oil
droplets were reported by the local investigators during slit-
lamp examination after 6 months of treatment. Several pa-
tients did report the presence of transient floaters, but whether
these were caused by silicone oil droplets remains unknown.
As in other clinical trials, the BRDME Study had its
limitations. First, it was missing a comparison with afli-
bercept, which unfortunately was not yet available in The
Netherlands at study start. The follow-up time was limited to
6 months, whereas patients with macular edema generally
are treated for a longer period. However, previous ran-
domized clinical trials demonstrated that improvement in
visual acuity occurs predominantly during the first 3 to 6
months of anti-VEGF therapy and that only limited visual
acuity gain is observed after this period.9,20,30,31 In addition,
6 initial monthly treatments can be regarded as standard care
for DME, and outcomes at 6 months are relevant for clinical
management, because at the 6-month time point after initi-
ation of anti-VEGF treatment, most ophthalmologists will
evaluate the need for additional deferred treatment with
laser, for switching drugs, or both. Not all participants were
treatment naïve; 16.7% in the bevacizumab group and
20.7% in the ranibizumab group received prior anti-VEGF
treatment. However, none of these patients had received
anti-VEGF therapy for at least 3 months, and all had a clear
indication for anti-VEGF therapy based on the inclusion
criteria. A total of 22 patients did not meet all eligibility
criteria, but because our study followed the intention-to-treat
principle, all patients were included in analyses. Besides,
primary and secondary outcomes were not altered when
these 22 participants were excluded from analysis. Patients
were divided into subgroups based on visual acuity outcome
at baseline and based on DR severity; however, our study
was not powered to reject noninferiority between treatment
arms in small subgroups. Nevertheless, the visual acuity
outcomes in the subgroup with a higher visual acuity were
suggestive of noninferiority in this subgroup alone. Finally,
different OCT devices were used for central area thickness
examination. To compare these outcomes, all measurements
were converted to Heidelberg Spectralis outcomes using the
conversion table by Giani et al.18 That said, the software
version of the devices used in this study differed from the
software versions on which Giani et al based their
Vader et al  Bevacizumab and Ranibizumab for DMEconversion table. Nevertheless, we expected minimal
changes to result from these software updates.
In conclusion, based on the difference in visual acuity
outcome, noninferiority of 1.25-mg bevacizumab to 0.5-mg
ranibizumab could not be confirmed in the treatment of
DME when patients received monthly injections for a period
of 6 months. In addition, anatomic outcomes on OCT also
differed markedly between treatment groups. Patients with a
lower baseline visual acuity showed an even better outcome
with 0.5-mg ranibizumab. After the Protocol T study of the
DRCR.net, our study is the first comparative trial to confirm
differences in efficacy between anti-VEGF agents, especially
in the subgroup of patients with a lower baseline visual acuity.
When taking the results of these studies together, clinicians
may be advised to treat patients with DME and a visual acuity
of worse than 20/40 with aflibercept or 0.5-mg ranibizumab,
rather than with 1.25-mg bevacizumab.
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